EN KR
Linkedin Facebook

Syntekabio Key Assets

Our platform has worked to identify druggable compounds and
increase your chances of discovering high-quality Hits & Leads.

런치패드 라이브러리

신테카바이오의 런치패드는 DeepMatcher®가 사전에 확보한 disease-specific 신약 후보물질 인벤토리입니다. 고객은 개발 단계에 따라 질병별, 타겟별로 준비된 후보물질을 선택할 수 있습니다. 단계별 맞춤 컨설팅과 최적화를 통해 후보물질을 빠르게 치료제로 개발할 수 있도록 다양한 AI 솔루션을 제공합니다. 현재 의약품의 60~70%를 주요 적응증으로 포괄하는 ~100개 단백질 타겟 목록입니다.

  • Indications
  • Top Notch Target#
  • Aim to Best in Class
  • Aim to First in Class
  • Autoimmune
    Psoriasis
    Atopic Dermatitis
    Alopecia
    Lupus
    Spondylarthritis
    Rheumatoid Arthritis
    Bowel Disease Syndrome
    7
    10
    ULK2, DYRK1A, ITK, NTRK1, S1PR1
    JAK3, IRAK4, TYK2, IRAK1, JAK1, JAK2, SYK
    SGK1, PRRT2
    TBK1, BTLA, ICOS
  • Cancer
    Breast Cancer
    Acute/Chronic Myeloid Leukemia
    Personalized Cancer Therapy
    Immune Checkpoint Inhibitors
    12
    11
    58
    10
    CLK2, CDK7, DYRK1A, ErbB2, ErbB4, CDK4, CDK6, CK2, CLK1, TNIK
    FLT3 ITD/F691L, ABL1, LYN, MKNK2, BCL2, IDH1, IDH2, DNMT3A
    ALK, BRAF V600E, CDK2, CDK7, CSF1R, DDR1, FGFR2, JAK3, KDM4D, KIT, MERTK1, MET M1250T, PI3KCA, RET, SRC, TGFR1, TIE2, ULK1, AKT1, AKT2, AR, AURKA, BCL2, CDK4, CDK6, DNMT3A, FNTA, FNTB, HDAC4, HDAC6, JAK1, JAK2, KRAS G12D, MEK1, MEK2, mTOR, PLK1
    IDO/TDO
    CLK4, DYRK2
    KC1D, PKN1, NPM1
    EPHB1, HASP, KDM4A, KDM5B, KGP2, PAK6, PI3KC3, ARID1A, ARID1B, ATK3, CASP8, CDKN2A, DNMT1, HDAC2, KDM5A, KDM6A, KDM7, MAP3K1, MLL3, SETD2, TP53 Y220C
    BTLA, CD112R, HAVCR2, ICOS, NKG2A, TIGIT, TNFRSF18, VISTA
  • CNS
    Major Depression
    Alzheimer’s Diseases
    Parkinson’s Diseases
    7
    13
    SLC6A4, DRD3, CACNA2D1, DRD2, SLC6A2
    CLK2, ACES+, PDE9A, PDE2A+, ROCK2+, PARP1, CK2, GSK3B
    CACNA1E, PXENL
    MLKL, PDE10A, CASP8, FADD, FAF1
  • Others
    COPD, viral infection, Peptic ulcer, Hypertension, I/R injury
    11
    MMP12, MK14, ACM2, AGTR1
    PI4KB, TNI3K, NEK7, ACE2, KDM2, KDM7
* STB definition “First in class” : target on Preclinical R&D stage (TOX, efficacy, experimental stage)
* STB definition “Best in class” : Targets on clinical development or approved stage (phase 1~)
Please contact us for drug list

send us your inquiry

SUBMIT
SUBMIT